Cerenome — Third Quarter 2026 Earnings Summary

Cerenome, Inc. reported third-quarter 2026 financial results showing $0.7 million in net diagnostic revenue and an operating loss of $7.5 million. The company expanded its payer coverage to approximately 190 million lives and launched CNSide molecular profiling tests for solid tumors and hematologic malignancies in October. Clinically, enrollment was completed in the Phase 2 ReSPECT-GBM trial for recurrent glioblastoma, while interim data from the ReSPECT-LM multi-dose study demonstrated safety with no dose-limiting toxicities. As of September 30, 2026, the company held $4.9 million in cash and investments, having recently secured a senior secured financing facility and raised additional equity.